Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Request metadata listed "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Stage: Development stage company focused on ex vivo production of human cells for cell and gene therapy. The company operates in one segment: research and product development.
Key Products: AastromReplicell System (instrumentation and kits), Tissue Repair Cells (TRCs), and Therapeutic Cells (TCs).
Key Financial Metrics
| Metric | Q3 2002 | Q3 2001 |
|---|---|---|
| Total Revenues | $93,000 | $151,000 |
| Net Loss | $(2,452,000) | $(1,893,000) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.05) |
| Cash and Cash Equivalents | $6,930,000 | $10,660,000 (End of Q3 2001) |
| Short-term Investments | $1,000,000 | $1,000,000 |
| Total Current Assets | $10,036,000 | $11,347,000 (June 30, 2002) |
| Total Current Liabilities | $835,000 | $750,000 (June 30, 2002) |
| Accumulated Deficit | $(96,249,000) | $(93,797,000) (June 30, 2002) |
Operating Expenses (Q3 2002): Total costs and expenses were $2,586,000, comprising $1,385,000 in R&D, $1,113,000 in SG&A, and $88,000 in cost of product sales.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 38% to $93,000 from $151,000 in the prior year quarter, primarily due to reduced grant program activity.
- Increased Loss: Net loss increased by $559,000 (30%) to $2,452,000. This was driven by higher operating expenses ($2,586,000 vs. $2,166,000) and lower interest income ($41,000 vs. $122,000).
- Expense Drivers: R&D expenses rose to $1,385,000 due to expanded program development. SG&A increased to $1,113,000, including a non-cash charge of $159,000 for warrants issued for investment banking services.
- Liquidity Reduction: Cash and cash equivalents decreased by $1,675,000 during the quarter to $6,930,000, primarily due to operating cash outflows of $2,544,000.
Guidance, Outlook, and Risks
Outlook and Funding: Management expects available cash to finance planned activities into the first quarter of fiscal year 2004. The company anticipates no positive cash flow from operations for several years. Additional funding is required to complete product development and commercialization. If funding is not secured by the end of the third quarter of fiscal year 2003, the company plans to make substantial reductions in operations.
New Developments: The company was awarded an $886,000 collaborative grant from the Defense Advanced Research Projects Agency (DARPA) beginning September 2002, expected to increase grant revenues in the coming fiscal year.
Key Risks:
- Delisting Risk: The company's stock price has traded below the $1.00 minimum bid price required for Nasdaq listing. Failure to regain compliance by February 24, 2003, could result in delisting.
- Supply Chain: A key supplier, Moll, filed for Chapter 11 bankruptcy in September 2002. While supply has not yet been impacted, the company is negotiating with alternative suppliers.
- Regulatory and Clinical: Commercialization depends on successful clinical trials and FDA approval. The company faces risks regarding patient enrollment delays and the safety/efficacy of its cell therapies.
- Inventory Obsolescence: The company recorded an $88,000 provision for obsolete inventory in Q3 2002. Future technological changes could lead to further write-downs.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next financing round, specifically the Q3 2003 deadline for operational reductions.
- Nasdaq Compliance: Monitor stock price performance to ensure compliance with the $1.00 minimum bid price requirement to avoid delisting.
- Supplier Stability: Confirm the status of the new supply agreement following Moll's bankruptcy filing.
- Grant Revenue: Track the realization of the $886,000 DARPA grant revenue in subsequent quarters.
- Inventory Valuation: Review future inventory write-downs given the company's limited sales history and aging inventory policies.